5-Chloro-N-((1S,2R)-3-((3R,4S)-3,4-dihydroxy-1-pyrrolidinyl))-2-hydroxy-3-oxo-1-(phenylmethyl)propyl-1H-indole-2-carboxamide,
CP-368,296,
ingliforib,
Ingliforib,
UNII-UII7156WLU,
186392-65-4,
UII7156WLU,
Ingliforib [USAN:INN],
CP-296,
Ingliforib (USAN/INN),
DSSTox_CID_27252,
DSSTox_RID_82211,
DSSTox_GSID_47252,
SCHEMBL122709,
CHEMBL2104888,
DTXSID4047252,
cp368296,
Tox21_300206,
NCGC00247928-01,
NCGC00253929-01,
HY-19396,
CP-368296,
CAS-186392-65-4,
CP-368,296,
CS-0015497,
D04537,
Q27291096,
(R-(R*,S*-(cis)))-5-chloro- N-(3-(3,4-dihydroxy-1-pyrrolidinyl)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl)-1H-indole-2-carboxamide,
(R-(R*,S*-(cis)))-5-Chloro-N-(3-(3,4-dihydroxy-1-pyrrolidinyl)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl)-1H-indole-2-carboxamide,
1H-Indole-2-carboxamide, 5-chloro-N-((1S,2R)-3-((3R,4S)-3,4-dihydroxy-1-pyrrolidinyl)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl)-,
Ingliforib [USAN],
C23H24ClN3O5,
CP-368,
C23-H24-Cl-N3-O5,
AC1O5362,
CID6451325,
5-chloro-N-[(2S,3R)-4-[(3R,4S)-3,4-dihydroxypyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-1H-indole-2-carboxamide,